Mebufotenin - GH Research
Alternative Names: 5 Methoxy N N dimethyltryptamine - GH Research; 5 Methoxy N,N Dimethyltryptamine; 5-MeO-DMT; GH-001; GH-002; GH-003Latest Information Update: 13 Aug 2024
At a glance
- Originator GH Research
- Class Antidepressants; Behavioural disorder therapies; Ethers; Mood stabilisers; Small molecules; Tryptamines
- Mechanism of Action Serotonin receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Bipolar disorders; Major depressive disorder; Postnatal depression
Most Recent Events
- 01 Aug 2024 GH Research Limited initiates a phase I pharmacokinetic and safety trial in Healthy volunteers in United Kingdom (Inhalation) (NCT06511947)
- 22 Jul 2024 GH Research plans a phase I safety and pharmacokinetics study in healthy subjects in United Kingdom (inhalation) in July 2024 (NCT06511947)
- 01 Mar 2024 GH Research has patent protection for crystalline hydrobromide salt of mebufotenin in European Union